A detailed history of Financial Perspectives, Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Financial Perspectives, Inc holds 2,422 shares of CRSP stock, worth $128,923. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,422
Previous 2,302 5.21%
Holding current value
$128,923
Previous $144 Million 14.56%
% of portfolio
0.06%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$60.67 - $89.12 $7,280 - $10,694
120 Added 5.21%
2,422 $165 Million
Q2 2023

Jan 09, 2024

BUY
$43.47 - $67.77 $19,170 - $29,886
441 Added 23.7%
2,302 $129 Million
Q4 2022

Jan 09, 2024

SELL
$39.19 - $65.67 $2,468 - $4,137
-63 Reduced 3.27%
1,861 $75.7 Million
Q3 2022

Jan 09, 2024

BUY
$61.1 - $83.78 $9,103 - $12,483
149 Added 8.39%
1,924 $126 Million
Q1 2022

Jan 09, 2024

BUY
$53.19 - $79.24 $4,255 - $6,339
80 Added 4.72%
1,775 $111 Million
Q4 2021

Jan 09, 2024

SELL
$70.09 - $111.29 $105,835 - $168,047
-1,510 Reduced 47.11%
1,695 $128 Million
Q3 2021

Jan 09, 2024

SELL
$110.2 - $156.64 $5,620 - $7,988
-51 Reduced 1.57%
3,205 $359 Million
Q2 2021

Jan 09, 2024

SELL
$100.84 - $161.89 $37.2 Million - $59.7 Million
-368,996 Reduced 99.13%
3,256 $527 Million
Q1 2021

Jan 09, 2024

BUY
$110.72 - $210.04 $41 Million - $77.8 Million
370,465 Added 20731.11%
372,252 $3.06 Million
Q4 2020

Jan 09, 2024

BUY
$79.67 - $173.23 $71,224 - $154,867
894 Added 100.11%
1,787 $274 Million
Q3 2020

Jan 09, 2024

BUY
$78.5 - $100.64 $46,236 - $59,276
589 Added 193.75%
893 $74.7 Million
Q4 2019

Jan 09, 2024

BUY
$36.68 - $73.13 $11,150 - $22,231
304 New
304 $18.5 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.15B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Financial Perspectives, Inc Portfolio

Follow Financial Perspectives, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Perspectives, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Financial Perspectives, Inc with notifications on news.